The Long & Winding Road
to Weight Loss

Download the white paper by filling out the form below.

Depending on your point of view, 2023 was either the year of Taylor Swift or Wegovy™. Each juggernaut is credited with fueling the economies of their countries of origin: in Swift’s case, the US, and in Wegovy’s case, Denmark. Denmark is the home of Novo Nordisk, which for 100 years quietly made drugs for diabetes before revolutionizing pharmaceutical weight loss with Wegovy (semaglutide), which is simply the type 2 diabetes drug Ozempic (also semaglutide) in different packaging. Just as Swift reimagined her songbook in her Eras tour, Novo Nordisk reinvented the treatment of weight loss and obesity. The road to success has been bumpy for both Swift and Novo Nordisk, which surely makes their triumphs all the sweeter.

In this white paper, we’ll take a closer look at the path to Wegovy, which is far longer and more winding than anyone might imagine.

Panalgo is a full scale analytics solutions provider, from data to insights.

Our suite of solutions includes streamlined access to data, industry-leading software, and expert analytics services.